Skip to content

BioXcel Therapeutics, Inc.

BTAI

CIK 0001720893

← back to feed
Revenue (TTM)
$592K
−71.7% YoY Q1 May 2026
Net Income (TTM)
−$70.04M
−17.3% YoY Q1 May 2026
EPS Diluted (TTM)
−$6.67
+75.6% YoY Q1 May 2026
Gross Margin
29.9%
Q1 May 2026
Operating Margin
-8,513.9%
Q1 May 2026
Net Margin
-11,831.6%
Q1 May 2026
Free Cash Flow (TTM)
−$94.35M
Q1 May 2026
Cash
$17.18M
Q1 May 2026
Total Debt
$100.29M
Q1 May 2026
Shares Outstanding
30.88M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings